Windlas Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on April 17, 2026.
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech Limited's Board has approved a buyback of up to 4,70,000 equity shares (2.23% of total paid-up capital) at INR 1,000 per share, totaling up to INR 47 crore. The buyback represents 9.80% of the company's aggregate paid-up equity share capital and free reserves based on audited financials as of March 31, 2025. The buyback will be conducted via the Tender Offer route, excluding promoters who have indicated they will not participate. The record date for determining eligible shareholders is fixed as April 24, 2026. A buyback committee has been formed, and Fintellectual Corporate Advisors has been appointed as the Manager to the Buyback.
The buyback at a 74% premium over the face value signals management confidence and provides liquidity to shareholders. The exclusion of promoters increases the buyback pool for retail investors. This should be positive for the stock price in the near term.